Nano-Based Targeted Drug Delivery for Lung Cancer: Therapeutic Avenues and Challenges

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp. Oncol. 25(1), 45–52 (2021).
   Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat. Rev. Dis. Primers 7(1), 3 (2021).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small-cell lung cancer. Nature 553(7689), 446–454 (2018).
   PubMed Web of Science ®Google Scholar
• Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim. Biophys. Acta 1856(2), 189–210 (2015).
   PubMed Web of Science ®Google Scholar
• Norouzi M, Hardy P. Clinical applications of nanomedicines in lung cancer treatment. Acta Biomater. 121, 134–142 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou J, Kang Y, Chen L et al. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol. 11, 343 (2020).
   PubMed Web of Science ®Google Scholar
• Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 47(19), 6645–6653 (2018).
   PubMed Web of Science ®Google Scholar
• Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Extending survival of stage IV non-small-cell lung cancer. Semin. Oncol. 41(1), 69–92 (2014).
   PubMed Web of Science ®Google Scholar
• Razak SA A, Mohd Gazzali A, Fisol FA et al. Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview. Cancers (Basel) 13(3), 400 (2021).
   PubMed Web of Science ®Google Scholar
• Shirakawa K, Takara K, Tanigawara Y et al. Interaction of docetaxel (“Taxotere”) with human P-glycoprotein. Jpn J. Cancer Res. 90(12), 1380–1386 (1999).
   PubMedGoogle Scholar
• Zaffaroni N, Pennati M, Colella G et al. Expression of the anti-apoptotic gene SURVIVIN correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59(8), 1406–1412 (2002).
   PubMed Web of Science ®Google Scholar
• Karpuz M, Silindir-Gunay M, Ozer AY. Clinical applications of nanosized drug-delivery systems in lung cancer imaging and therapy. Crit. Rev. Ther. Drug Carrier Syst. 37(5), 435–471 (2020).
   PubMed Web of Science ®Google Scholar
• Yu HP, Aljuffali IA, Fang JY. Injectable drug-loaded nanocarriers for lung cancer treatments. Curr. Pharm. Des. 23(3), 481–494 (2017).
   PubMed Web of Science ®Google Scholar
• AlSawaftah NM, Awad NS, Paul V, Kawak PS, Al-Sayah MH, Husseini GA. Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells. Sci. Rep. 11(1), 11589 (2021).
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? Drug Discov. Today Technol. 9(2), e71–e174 (2012).
   Google Scholar
• Hussain S. Nanomedicine for treatment of lung cancer. Adv. Exp. Med. Biol. 890, 137–147 (2016).
   PubMed Web of Science ®Google Scholar
• Gangopadhyay S, Nikam RR, Gore KR. Folate receptor-mediated siRNA delivery: recent developments and future directions for RNAi therapeutics. Nucleic Acid Ther. 31(4), 245–270 (2021).
   PubMed Web of Science ®Google Scholar
• Yao W, Yao J, Qian F et al. Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer. Acta Biochim. Biophys. Sin. (Shanghai) 53(8), 1027–1036 (2021).
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: a hepatologist’s perspectives. Eur. J. Pharmacol. 893, 173832 (2021).
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Z, Deng H, Zheng Z. Cinobufagin-loaded and folic acid-modified polydopamine nanomedicine combined with photothermal therapy for the treatment of lung cancer. Front. Chem. 9, 637754 (2021).
   PubMed Web of Science ®Google Scholar
• Kotta-Loizou I, Giaginis C, Theocharis S. Clinical significance of HuR expression in human malignancy. Med. Oncol. 31(9), 161 (2014).
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhang F, Zhou C et al. Human antigen R and drug resistance in tumors. Invest. New Drugs 37(5), 1107–1116 (2019).
   PubMed Web of Science ®Google Scholar
• Muralidharan R, Mehta M, Ahmed R et al. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci. Rep. 7(1), 9694 (2017).
   PubMedGoogle Scholar
• Amreddy N, Babu A, Panneerselvam J et al. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14(2), 373–384 (2018).
   PubMed Web of Science ®Google Scholar
• Xu F, Gu J, Lu C et al. Calpain-2 enhances non-small-cell lung cancer progression and chemoresistance to paclitaxel via EGFR-pAKT pathway. Int. J. Biol. Sci. 15(1), 127–137 (2019).
   PubMed Web of Science ®Google Scholar
• Park YI, Kwon SH, Lee G et al. pH-sensitive multi-drug liposomes targeting folate receptor β for efficient treatment of non-small-cell lung cancer. J. Control. Rel. 330, 1–14 (2021).
   PubMed Web of Science ®Google Scholar
• Rawal S, Bora V, Patel B, Patel M. Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small-cell lung cancer. Drug Deliv. Transl. Res. 11(5), 2030–2051 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang J, Shi W, Xue G, Ma Q, Cui H, Zhang L. Improved therapeutic efficacy of topotecan against A549 lung cancer cells with folate-targeted topotecan liposomes. Curr. Drug Metab. 21(11), 902–909 (2020).
   PubMed Web of Science ®Google Scholar
• Joerger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non-small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr. Drug Targets 11(1), 37–47 (2010).
   PubMed Web of Science ®Google Scholar
• Ak G, Aksu D, Çapkın E, Sarı Ö, Kımız Geboloğlu I, Şanlıer ŞH. Delivery of pemetrexed by magnetic nanoparticles: design, characterization, in vitro and in vivo assessment. Prep. Biochem. Biotechnol. 50(3), 215–225 (2020).
   PubMed Web of Science ®Google Scholar
• Gammella E, Buratti P, Cairo G, Recalcati S. The transferrin receptor: the cellular iron gate. Metallomics 9(10), 1367–1375 (2017).
   PubMed Web of Science ®Google Scholar
• Kawabata H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 133, 46–54 (2019).
   PubMed Web of Science ®Google Scholar
• De Vico G, Martano M, Maiolino P, Carella F, Leonardi L. Expression of transferrin receptor-1 (TFR-1) in canine osteosarcomas. Vet. Med. Sci. 6(3), 272–276 (2020).
   PubMed Web of Science ®Google Scholar
• Hagag AA, Badraia IM, Abdelmageed MM, Hablas NM, Hazzaa SME, Nosair NA. Prognostic value of transferrin receptor-1 (CD71) expression in acute lymphoblastic leukemia. Endocr. Metab. Immune. Disord. Drug Targets 18(6), 610–617 (2018).
   PubMed Web of Science ®Google Scholar
• Calzolari A, Oliviero I, Deaglio S et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol. Dis. 39(1), 82–91 (2007).
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu J, Chen J, Zou M, Rusidanmu A, Yang R. Blocking transferrin receptor inhibits the growth of lung adenocarcinoma cells in vitro. Thorac. Cancer 9(2), 253–261 (2018).
   PubMed Web of Science ®Google Scholar
• Whitney JF, Clark JM, Griffin TW, Gautam S, Leslie KO. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates. Cancer 76(1), 20–25 (1995).
   PubMed Web of Science ®Google Scholar
• Chan MH, Chan YC, Liu RS, Hsiao M. A selective drug delivery system based on phospholipid-type nanobubbles for lung cancer therapy. Nanomedicine (Lond.) 15(27), 2689–2705 (2020).
   PubMed Web of Science ®Google Scholar
• Wu YL, Ahn MJ, Garassino MC et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J. Clin. Oncol. 36(26), 2702–2709 (2018).
   PubMed Web of Science ®Google Scholar
• Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small-cell lung carcinoma. J. Neurooncol. 111(1), 1–10 (2013).
   PubMed Web of Science ®Google Scholar
• Li W, Sparidans RW, Wang Y et al. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Int. J. Cancer 143(8), 2029–2038 (2018).
   PubMed Web of Science ®Google Scholar
• Wang X, Mao W, Wang Z et al. Enhanced anti-brain metastasis from non-small-cell lung cancer of osimertinib and doxorubicin co-delivery targeted nanocarrier. Int. J. Nanomed. 15, 5491–5501 (2020).
   PubMed Web of Science ®Google Scholar
• Tan S, Wang G. Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed. Pharmacother. 102, 55–63 (2018).
   PubMed Web of Science ®Google Scholar
• Rampado R, Crotti S, Caliceti P, Pucciarelli S, Agostini M. Recent advances in understanding the protein corona of nanoparticles and in the formulation of “stealthy” nanomaterials. Front. Bioeng. Biotechnol. 8, 166 (2020).
   PubMed Web of Science ®Google Scholar
• Corbo C, Molinaro R, Parodi A, Toledano Furman NE, Salvatore F, Tasciotti E. The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond.) 11(1), 81–100 (2016).
   PubMed Web of Science ®Google Scholar
• Yu L, Xu M, Xu W et al. Enhanced cancer-targeted drug delivery using precoated nanoparticles. Nano Lett. 20(12), 8903–8911 (2020).
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Zullo L, Rossi G et al. Novel emerging molecular targets in non-small-cell lung cancer. Int. J. Mol. Sci. 22(5), 2625 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Cheng W, Pan Y, Jia L. An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer. J. Mater. Chem. B 8(4), 655–665 (2020).
   PubMed Web of Science ®Google Scholar
• Jha A, Viswanadh MK, Burande AS et al. DNA biodots based targeted theranostic nanomedicine for the imaging and treatment of non-small-cell lung cancer. Int. J. Biol. Macromol. 150, 413–425 (2020).
   PubMed Web of Science ®Google Scholar
• Madajewski B, Chen F, Yoo B et al. Molecular engineering of ultrasmall silica nanoparticle-drug conjugates as lung cancer therapeutics. Clin. Cancer Res. 26(20), 5424–5437 (2020).
   PubMed Web of Science ®Google Scholar
• Pang J, Xing H, Sun Y, Feng S, Wang S. Non-small-cell lung cancer combination therapy: hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. Biomed. Pharmacother. 125, 109861 (2020).
   PubMed Web of Science ®Google Scholar
• Aksorn N, Chanvorachote P. Integrin as a molecular target for anti-cancer approaches in lung cancer. Anticancer Res. 39(2), 541–548 (2019).
   PubMed Web of Science ®Google Scholar
• Yan P, Zhu H, Yin L et al. Integrin αvβ6 promotes lung cancer proliferation and metastasis through upregulation of IL-8-mediated MAPK/ERK signaling. Transl. Oncol. 11(3), 619–627 (2018).
   PubMed Web of Science ®Google Scholar
• Elayadi AN, Samli KN, Prudkin L et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for non-small-cell lung cancer. Cancer Res. 67(12), 5889–5895 (2007).
   PubMed Web of Science ®Google Scholar
• Guthi JS, Yang SG, Huang G et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm. 7(1), 32–40 (2010).
   PubMedGoogle Scholar
• Kariya Y, Oyama M, Suzuki T, Kariya Y. αvβ3 integrin induces partial EMT independent of TGF-β signaling. Commun. Biol. 4(1), 490 (2021).
   PubMed Web of Science ®Google Scholar
• Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9(11), 2961–2973 (2012).
   PubMed Web of Science ®Google Scholar
• Fu S, Zhao Y, Sun J et al. Integrin αvβ3-targeted liposomal drug delivery system for enhanced lung cancer therapy. Colloids Surf. B Biointerfaces 201, 111623 (2021).
   PubMed Web of Science ®Google Scholar
• Raniszewska A, Kwiecień I, Rutkowska E, Rzepecki P, Domagała-Kulawik J. Lung cancer stem cells – origin, diagnostic techniques and perspective for therapies. Cancers (Basel) 13(12), 2996 (2021).
   PubMed Web of Science ®Google Scholar
• Huang X, Wan J, Leng D, Zhang Y, Yang S. Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells. Exp. Ther. Med. 19(1), 192–204 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia Q, Wu T et al. A novel multi-functionalized multicellular nanodelivery system for non-small-cell lung cancer photochemotherapy. J. Nanobiotechnol. 19(1), 245 (2021).
   PubMed Web of Science ®Google Scholar
• Shahriari M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M. Self-targeted polymersomal co-formulation of doxorubicin, camptothecin and FOXM1 aptamer for efficient treatment of non-small-cell lung cancer. J. Control. Rel. 335, 369–388 (2021).
   PubMed Web of Science ®Google Scholar
• Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small-cell lung cancer cells. Life Sci. 66(20), 1979–1986 (2000).
   PubMed Web of Science ®Google Scholar
• Kim MS, Haney MJ, Zhao Y et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine 14(1), 195–204 (2018).
   PubMed Web of Science ®Google Scholar
• Garizo AR, Castro F, Martins C et al. p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer. J. Control. Rel. 337, 329–342 (2021).
   PubMed Web of Science ®Google Scholar
• Mehta HJ, Patel V, Sadikot RT. Curcumin and lung cancer – a review. Target Oncol. 9(4), 295–310 (2014).
   PubMed Web of Science ®Google Scholar
• Giordano A, Tommonaro G. Curcumin and cancer. Nutrients 11(10), 2376 (2019).
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D, Sokal E, Karthikeyan S, Najimi M. Plant derived antioxidants and antifibrotic drugs: past, present and future. J. Coast. Life Med. 2(9), 738–745 (2014).
   Google Scholar
• Almasi CE, Drivsholm L, Pappot H, Høyer-Hansen G, Christensen IJ. The liberated domain I of urokinase plasminogen activator receptor – a new tumour marker in small-cell lung cancer. APMIS 121(3), 189–196 (2013).
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B et al. Lung cancer therapy using doxorubicin and curcumin combination: targeted prodrug based, pH sensitive nanomedicine. Biomed. Pharmacother. 112, 108614 (2019).
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Tagami T, Kishi T, Ozeki T. Curcumin marinosomes as promising nano-drug delivery system for lung cancer. Int. J. Pharm. 540(1–2), 40–49 (2018).
   PubMed Web of Science ®Google Scholar
• Mahmoodi Chalbatani G, Dana H, Gharagouzloo E et al. Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach. Int. J. Nanomed. 14, 3111–3128 (2019).
   PubMed Web of Science ®Google Scholar
• Kara G, Parlar A, Cakmak MC, Cokol M, Denkbas EB, Bakan F. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy. Colloids Surf. B Biointerfaces 196, 111340 (2020).
   PubMed Web of Science ®Google Scholar
• Akbaba H, Erel-Akbaba G, Kotmakçı M, Başpınar Y. Enhanced cellular uptake and gene silencing activity of survivin-siRNA via ultrasound-mediated nanobubbles in lung cancer cells. Pharm. Res. 37(8), 165 (2020).
   PubMed Web of Science ®Google Scholar
• Yang Y, Han Y, Sun Q et al. Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy. J. Nanobiotechnol. 19(1), 54 (2021).
   PubMed Web of Science ®Google Scholar
• Anagnostou VK, Lowery FJ, Zolota V et al. High expression of BCL-2 predicts favorable outcome in non-small-cell lung cancer patients with non-squamous histology. BMC Cancer 10, 186 (2010).
   PubMed Web of Science ®Google Scholar
• D’Aguanno S, Del Bufalo D. Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer. Cells 9(5), 1287 (2020).
   PubMed Web of Science ®Google Scholar
• Chen S, Ren Y, Duan P. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling. Biomed. Pharmacother. 129, 110371 (2020).
   PubMed Web of Science ®Google Scholar
• Devaraj E, Perumal E, Subramaniyan R, Najimi M. Liver fibrosis: extracellular vesicles mediated intercellular communication in perisinusoidal space. Hepatology doi: 10.1002/hep.32239 (2021).
   PubMed Web of Science ®Google Scholar
• Wang Y, Guo M, Lin D et al. Docetaxel-loaded exosomes for targeting non-small-cell lung cancer: preparation and evaluation in vitro and in vivo. Drug Deliv. 28(1), 1510–1523 (2021).
   PubMed Web of Science ®Google Scholar
• Lathwal S, Yerneni SS, Boye S et al. Engineering exosome polymer hybrids by atom transfer radical polymerization. Proc. Natl Acad. Sci. USA 118(2), e2020241118 (2021).
   PubMed Web of Science ®Google Scholar
• Bertino EM, Williams TM, Nana-Sinkam SP et al. Stromal caveolin-1 is associated with response and survival in a phase II trial of nab-paclitaxel with carboplatin for advanced NSCLC patients. Clin. Lung Cancer 16(6), 466–474 (2015).
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128ra39 (2012).
   PubMed Web of Science ®Google Scholar
• Zhu HZ, Hou J, Guo Y et al. Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles. Drug Deliv. 25(1), 1974–1983 (2018).
   PubMed Web of Science ®Google Scholar
• Itani R, Al Faraj A. siRNA conjugated nanoparticles – a next generation strategy to treat lung cancer. Int. J. Mol. Sci. 20(23), 6088 (2019).
   PubMed Web of Science ®Google Scholar
• Wu R, Zhang Z, Wang B et al. Combination chemotherapy of lung cancer – co-delivery of docetaxel prodrug and cisplatin using aptamer-decorated lipid-polymer hybrid nanoparticles. Drug Des. Devel. Ther. 14, 2249–2261 (2020).
   PubMed Web of Science ®Google Scholar
• de Braganca L, Ferguson GJ, Luis Santos J, Derrick JP. Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung. J. Immunotoxicol. 18(1), 61–73 (2021).
   PubMed Web of Science ®Google Scholar